Product Description
Mechanisms of Action: Sirt1 Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sirtris
Company Location: CAMBRIDGE MA 02139
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Type 2 Diabetes|Psoriasis
Phase 1: Type 2 Diabetes|Muscular Atrophy|Psoriasis|Colitis, Ulcerative|Chronic Obstructive Pulmonary Disease|Sepsis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT01453491 | P1 |
Completed |
Colitis, Ulcerative |
2013-03-18 |
|
| NCT01702493 | P1 |
Completed |
Psoriasis |
2012-12-05 |
|
| NCT01154101 | P2 |
Completed |
Psoriasis |
2011-11-09 |
|
| NCT01031108 | P1 |
Completed |
Type 2 Diabetes |
2011-10-12 |
|
| SRT-2104-003 | P1 |
Withdrawn |
Muscular Atrophy |
2011-02-01 |
|
| NCT01018017 | P2 |
Completed |
Type 2 Diabetes |
2010-12-25 |
|
| 2009-016537-98 | P2 |
Completed |
Type 2 Diabetes |
2010-12-22 |
|
| NCT00937326 | P2 |
Completed |
Type 2 Diabetes |
2010-09-18 |
|
| NCT01014117 | P1 |
Completed |
Sepsis |
2010-05-10 |
|
| NCT00964340 | P1 |
Completed |
Muscular Atrophy |
2010-04-27 |
|
| NCT00920660 | P1 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-06-12 |
|
| NCT00933062 | P1 |
Completed |
Type 2 Diabetes |
2009-05-12 |
|
| NCT00938275 | P1 |
Completed |
Type 2 Diabetes |
2009-03-27 |
|
| NCT00937872 | P1 |
Completed |
Type 2 Diabetes |
2008-12-22 |
|
| NCT00933530 | P1 |
Completed |
Type 2 Diabetes |
2008-11-01 |